Closing soon: reversing decline proven in animals and advancing to humans

wefunder

Rejuvenate Bio develops one-shot gene therapies aimed at addressing aging and chronic disease by reprogramming the body's function. The company originated from the laboratory of George Church at Harvard Medical School and is led by scientists with backgrounds in genetics, synthetic biology, engineering, and gene therapy. Its platform aims to restore youthful biology in both humans and companion animals.

The company operates two core platforms. Platform 1 is a liver-directed gene therapy that delivers the FGF21 gene via an AAV8 vector to the liver, with the goal of restoring youthful FGF21 levels to regulate metabolism, inflammation, and tissue repair. In preclinical models, this approach has shown reversal of cardiac damage and improvement in metabolic function. Platform 2 centers on epigenetic reprogramming, which resets gene expression without altering DNA, by selectively activating transcription factors. In preclinical models, this approach has been associated with extended remaining lifespan, improved physical performance, and rejuvenation of nerve and vision function.

Rejuvenate Bio has developed a proprietary high-yield manufacturing system that reduces production costs, with doses produced at under $100. The company pursues a dual-market strategy that leverages animal health partnerships to fund research and manufacturing while generating milestone and royalty streams, and uses data and manufacturing efficiencies to support its human programs. Notable animal health partnerships include multi-year development and commercialization agreements with Phibro and Protect Animal Health, which provide near-term inflows and long-term royalty potential.

Current indicators include more than $130 million in contracted development and commercial milestone payments, along with cumulative payments and in-kind services from partners. Royalties on partner sales are expected to begin in the future as programs reach commercial milestones. The business model emphasizes rapid pipeline expansion across cardiovascular, metabolic, and neurodegenerative diseases, with a focus on translating animal data to human programs to accelerate readouts and reduce capital needs. The company notes progress toward cash flow positivity through its capital-efficient framework and animal-human program integration. Recognized by Harvard Business School and MIT Technology Review for pioneering work in reversing aging and extending healthspan, Rejuvenate Bio is led by founders Daniel Oliver and Dr. Noah Davidsohn, who collaborate with scientists and advisors from top institutions to advance regenerative medicine.

Daniel Oliver

Co-Founder & CEO

Noah Davidsohn

Co-Founder & CSO

George Church

Co-Founder & Scientific Advisor

Dr. Fabian Kausche

Animal Health Advisor

Eric Hacherl

Manufacturing

Joseph Consiglio

Strategic Processes

Jeff Rudy

R&D Scale

Dr. Maritza McIntyre

Consultant (Advanced Therapies Partners)

Richard Peluso

Consultant (RWP BioConsulting)

Chien-Hung (Chris) Liu

Consultant

Rejuvenate Bio

Rejuvenate Bio has started monthly meetings with the FDA’s Veterinary Innovation Program for its lead gene therapy for heart disease in dogs, and co-founder/CSO Noah participates every month. The company also submitted its first safety protocol for review and says the investor round will not stay open much longer.

Rejuvenate Bio begins monthly FDA Veterinary Innovation Program meetings and submits first safety protocol

Rejuvenate Bio describes its lead gene therapy for mitral valve disease (RJB-01c) partnerships with Phibro Animal Health and Protect Animal Health, citing planned U.S. and Asia-Pacific commercialization rights. The Protect Animal Health deal included $4.5M in upfront payments, and the company says its animal health partnerships total $130M+ in contracted development and commercial milestones.

Rejuvenate Bio highlights partners for MVD gene therapy: Phibro and Protect Animal Health

Rejuvenate Bio says its community round is closing soon, reporting 1,200+ investors and $3M+ raised on Wefunder. The update states the company has reversed cardiac disease in dogs (gene therapy), is in the FDA Veterinary Innovation Program with a new dog trial pending final protocol sign-off, has $130M+ in contracted milestones with Phibro Animal Health (with Merck Animal Health investment in a $6M institutional round), has raised $36M+ from Tier 1 investors, and plans first human dosing about a year away with an initial trial in 2027 (up to 20 patients, forward-looking).

Community round closing soon; $3M+ raised and investors, milestones, and trial plans

AgeTech World published a feature on Rejuvenate Bio, including the company’s timeline to its first human trial. Rejuvenate Bio says it plans to dose its first human patient roughly a year from now, open an initial trial in 2027 with up to 50 patients for arrhythmogenic cardiomyopathy, and later expand in Phase 3; it also states it has raised $36M+ from Tier 1 biotech investors.

AgeTech feature and timeline to Rejuvenate Bio’s first human trial

Rejuvenate Bio says investor Chris Graebe of IPO Deal Hunter invested in the company after deep due diligence, and that a strategic investment from Merck Animal Health supports its exit potential. The update also claims Rejuvenate Bio is about to oversubscribe for the second time and invites readers to invest or increase their investment on Wefunder.

Deal hunter Chris Graebe invests in Rejuvenate Bio

Rejuvenate Bio reports it has nearly hit its investment goal for the second time after expanding its community round in August, and says it is currently the #1 most-raised active community round on Wefunder. The company also states it is on track for a new dog trial pending final FDA protocol sign-off, and plans fall conference appearances including September 16, October 1 (Toronto), and October 9 (Denver).

Rejuvenate Bio Q3 update: nearing community investment goal again; FDA protocol sign-off pending for new dog trial

Rejuvenate Bio says it is almost at $3M raised from more than 1,000 investors since opening more room in the round. The company states the round is funding progress toward human clinical trials for its gene therapy platform in cardiac disease in dogs.

Rejuvenate Bio nears $3M raised from over 1,000 investors

Rejuvenate Bio reports welcoming its 1,000th investor to its community round and states the round has raised $2.6M+ and is already 85% funded toward its next goal. The update also highlights contracted milestone commitments of $130M+ with partners including Phibro Animal Health and mentions zero safety signals in its lead gene therapy program and manufacturing cost per dose under $100.

Rejuvenate Bio crosses 1,000 investors and reports $2.6M+ raised; 85% funded toward next goal

Rejuvenate Bio says it has raised $36M+ with contracted payments of $130M+ secured and is inviting its community to invest alongside institutional capital in a coexisting institutional/community round. The update also mentions similar Wefunder community rounds from Koios Medical (FDA-cleared AI software) and Siren Biotechnology.

Why biotech is opening community rounds to everyday investors (Rejuvenate Bio update)

The update explains that mitral valve disease affects roughly 7% of all dogs and accounts for about 75% of canine heart disease, with Cavalier King Charles Spaniels showing incidence approaching 80%. Rejuvenate Bio’s lead program RJB-01c targets mitral valve disease; in treated dogs, a single one-time injection delayed disease progression by more than a year and a half versus standard of care, and the company describes domestic rights partnered to Phibro Animal Health and collaboration with the American Cavalier King Charles Spaniel Club.

Why Cavaliers are central to Rejuvenate Bio’s roadmap

Rejuvenate Bio says its oversubscribed Wefunder community investment round has been extended, with 900+ investors committing $2.4M in addition to a $6M financing round (nearly 200% over the original goal). The company completed a full financial audit to enable raising beyond $1.2M under SEC rules and filed paperwork with the SEC to raise more; it has raised $8.5M to date and does not expect another community round after this one closes.

Rejuvenate Bio extends oversubscribed Wefunder round; 900+ investors commit $2.4M

Rejuvenate Bio explains its animal-first approach, arguing it generates safety and efficacy data to inform human programs. The update also claims partnerships with animal health companies like Merck and Phibro represent $130M+ in contracted development and commercial milestones, and encourages readers to invest or increase their investment.

Why Rejuvenate Bio’s animal-first approach supports faster human medicine

The update says Rejuvenate Bio has delayed cardiac disease progression in dogs by 600+ days versus standard of care after a single gene therapy injection. It also claims Merck Animal Health invested alongside Rejuvenate Bio’s $6M round led by VCapital and that the company has $130M+ in contracted development and commercial milestones, and is oversubscribed but still accepting investments via this community round.

Rejuvenate Bio: five reasons to invest, including Merck investment and contracted milestones

Rejuvenate Bio’s community round has crossed $2M, raised from more than 750 investors, making it the #1 most-funded campaign on Wefunder. The update also says Merck joined its $6M round, and the company is using the momentum to advance its lead gene therapy toward human clinical trials.

Rejuvenate Bio community round crosses $2M; top-funded on Wefunder

Rejuvenate Bio says it closed a $6M round led by VCapital with an investment from Merck Animal Health and a strategic R&D collaboration. The company also reports treating cardiac disease in dogs with a single gene therapy injection, supported by three years of safety data and zero adverse events.

Rejuvenate Bio announces $6M round close and dog gene-therapy results

A replay is shared of a webinar where VCapital’s Ryan Kole and Connecticut Innovations’ Megha Unhelkar discussed what drove their diligence before investing in Rejuvenate Bio’s $6M round, citing no safety issues, durable long-term effects, and performance beating the current standard of care, plus reduced gene-therapy production costs. The company says the round is oversubscribed and it is extending the round to make room for additional investors, with remaining allocation going fast.

Replay: VC partners discuss what drove their conviction in Rejuvenate Bio’s $6M round

Kingscrowd rated and reviewed Rejuvenate Bio’s public investment round, giving it 4.9/5.0 and investing $20,000. The update says Kingscrowd highlighted the company’s gene-therapy approach, a “funding flywheel” supported by $130M+ in contracted milestones across six animal health partners, and an estimated ~$100 cost to manufacture a one-time therapeutic dose.

Kingscrowd rated Rejuvenate Bio 4.9/5 and invested $20,000 in the round

Rejuvenate Bio will host a live Zoom Q&A on Tuesday, June 30 at 12pm ET / 9am PT where VCapital (which led Rejuvenate Bio’s $6M round with Merck Animal Health) and Connecticut Innovations will explain why they invested. The update says the round is oversubscribed, with additional allocation opened and remaining space expected to go fast; registration link is provided.

Live Q&A on June 30: VCapital and Connecticut Innovations investors discuss their diligence

Rejuvenate Bio was ranked the #2 most-funded community round in the country last week by Kingscrowd. Its $6M round backed by Merck Animal Health is now oversubscribed, so the company is opening additional capacity for investors to reserve their stake for the next allocation.

Kingscrowd ranks Rejuvenate Bio #2; $6M round oversubscribed and adding capacity

Rejuvenate Bio says it opened its public round last week and has raised over $1M on Wefunder, bringing the total raised in the round to $7M+. The update claims the round is almost sold out and highlights backing for its gene-therapy technology and prior milestones.

Rejuvenate Bio says its round is almost sold out and reports $7M+ raised

Rejuvenate Bio says it won the Judges' Choice Award at the Superpowers for Good Live Pitch on the e360tv Network. The update claims three years of animal safety data with zero adverse events, reversal of cardiac disease in dogs, $130M+ in contracted milestones with animal health partners, and that its Wefunder community round is oversubscribed and reopened for additional investors before it sells out again.

Rejuvenate Bio wins Judges' Choice Award at nationally broadcast investor pitch event

Merck Animal Health invested in Rejuvenate Bio’s $6M financing round led by VCapital alongside Digitalis and Connecticut Innovations. The company also entered a strategic research and development collaboration with Merck focused on a novel animal-health gene therapy program, and Rejuvenate Bio says its Wefunder round is now oversubscribed.

Merck Animal Health invests in Rejuvenate Bio’s $6M financing round

Rejuvenate Bio’s Wefunder round is officially open to the public. The update states it has raised $30M+ (including Tier 1 investors) and reports $130M+ in contracted partner milestones with Phibro Animal Health, plus three years of dog cardiac disease safety data with zero adverse events.

Rejuvenate Bio round opens to the public

The company says its private investment window on Wefunder is closing and the round will open to 1M+ investors in a few days. It reports 130+ investors have already joined and claims Kingscrowd ranked it #14 most raised across all platforms last week, with the institutional round wrapping up and more details coming soon.

Rejuvenate Bio closing private investment window and opening round to 1M+ investors

The update claims Rejuvenate Bio delayed progression of cardiac disease in dogs by over 600 days versus standard of care, citing three years of safety data with zero adverse events. It also states the company has raised $40M+ including $13M+ in non-dilutive U.S. Department of Defense funding and has $130M+ in contracted milestones with Phibro Animal Health and other animal health companies.

5 reasons to back Rejuvenate Bio

Rejuvenate Bio says it has officially filed its Regulation Crowdfunding paperwork with the SEC, making its community round live so it can begin accepting investments. The update also references a Galaxy Balance podcast episode discussing the biology of aging and how its combination gene therapies work.

Rejuvenate Bio files SEC Regulation Crowdfunding paperwork; community round is now live

Rejuvenate Bio says it has officially filed its Reg CF paperwork with the SEC, and the early-bird allocation is fully reserved. The update asks prior “testing the waters” reservers to confirm their investment to claim preferred terms and says the round is currently open exclusively to early supporters.

Rejuvenate Bio Files Reg CF Paperwork With SEC; Early-Bird Allocation Fully Reserved

Rejuvenate Bio is hosting a live webinar on March 10 with Noah and Dr. Nicole Paulk, CEO and Founder of Siren Biotechnology, to discuss myths about gene therapy. The update includes the webinar time (10am PT / 1pm ET) and registration on Zoom, with limited seats.

Live webinar: Debunking Gene Therapy Myths with Siren Biotechnology (Dr. Nicole Paulk)

In July 2025, Harvard Business School published a case study on Rejuvenate Bio (“Rejuvenate Bio: Turning Back the Biological Clock”). The update also states the company has secured $130M in development and commercial milestone payments, with $5.1M already received, and invites readers to request the full case details.

Harvard Business School publishes a case study; company reports receiving $5.1M of $130M in milestones

Two major animal health companies have signaled strong interest in partnering on feline chronic kidney disease, and R&D partnership negotiations are underway with a major animal health company on its next platform. A paper from its human program has been accepted for publication, and the founder also mentions an upcoming MIT event and registration link.

Rejuvenate Bio reports partnership interest, accepted publication, and upcoming MIT talk

Rejuvenate Bio says the founder webinar replay is now live, describing its gene therapy platform for mitral valve disease in dogs, obesity and chronic kidney disease in cats, and cardiometabolic conditions in humans. The update cites $5.1M in partner payments, double-digit-million royalties starting in 2028, and a capital-efficient path to cash-flow positivity with $3–4M, plus an early-investor opportunity before reaching cash-flow positivity and opening to new investors.